Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reaches Key LibiGel® Safety Study Enrollment Target
First Unblinded Statistical Analysis to be Conducted on 2,500 Women
LINCOLNSHIRE, Ill. - October 18, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events. LibiGel is being developed for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
The DMC's unblinded statistical analysis will determine whether the current study enrollment of 2,500 is sufficient to prove statistically the relative safety of LibiGel compared to placebo after an average of 12 months of exposure is reached, or if enrollment will continue. To date, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, and only seven diagnoses of breast cancer, a rate of approximately 0.32 percent, after approximately 2,300 women-years of exposure in the study. BioSante will remain blinded as to the distribution of the reported safety events between the active and placebo study arms.
If enrollment continues beyond 2,500 women, an additional unblinded statistical analysis will be conducted by the DMC each time a new cardiovascular event is adjudicated. At each of these analyses the trial potentially could be fully enrolled. If enrollment is not completed sooner, enrollment will continue until the study reaches its predetermined maximum of 4,000 women.
"This milestone gives BioSante our first opportunity potentially to declare completion of enrollment in the safety study," stated Michael Snabes, M.D., Ph.D., BioSante's senior vice president of medical affairs. "We have had an extremely low number of cardiovascular and breast cancer events to date, as well as three previous favorable DMC recommendations. We expect the study to demonstrate the safety of LibiGel in the treated population, regardless of whether the DMC stops enrollment at 2,500 women or we need to continue enrollment."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that will enroll between 2,500 and 4,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 month exposure to LibiGel or placebo. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after a once-daily pea-sized application on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Monday, October 18, 2010
Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected for Second Profile in Influential UK-Based Public Service Review, as Outbreak of Legionnaires Disease Draws Renewed Attention to Dangers of Airborne Bacteria
Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected for Second Profile in Influential UK-Based Public Service Review, as Outbreak of Legionnaires Disease Draws Renewed Attention to Dangers of Airborne Bacteria
CENTERVILLE, MA - October 18, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.
The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the 'Review' as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."
Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/ Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
CENTERVILLE, MA - October 18, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.
The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the 'Review' as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."
Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/ Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Sunday, October 17, 2010
Biotech Stocks to Watch for Monday; (OTCBB: UVFT), (AMEX: PIP), (NASDAQ:VVUS), (NASDAQ: AMGN)
Biotech Stocks to Watch for Monday; (OTCBB: UVFT), (AMEX: PIP), (NASDAQ:VVUS), (NASDAQ: AMGN)
Point Roberts, WA –October 17, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research for investors, reports on recent Biotech/ Pharma Stocks news and trading. Biotech Stocks to follow for Monday morning include UV Flu Technologies, Inc., (OTCBB: UVFT), PharmAthene, Inc. (AMEX: PIP), VIVUS Inc (NASDAQ:VVUS), and Amgen Inc., (NASDAQ: AMGN).
Biotech Sector Snapshot: (Trading at Market close Friday October 15)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.27
PharmAthene, Inc. (AMEX: PIP), trading at $ 3.19, up 1.21 (61.11%) on Volume of 22,685 ,355 shares
VIVUS Inc (NASDAQ:VVUS), trading at $6.53, (0.76 %)
Amgen Inc., (NASDAQ: AMGN) trading at $ 56.71, up 1.85 (3.37%)
Biotech Stocks to Watch; Recent News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
Latest News:
UV Flu Technologies Announces Development of Residential Market Bacteria Killing Indoor Air Purifier to Be Based on Laboratory Proven Design
“UV Flu Technologies, Inc. is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace. The new unit will be designated UV-200 and will be designed with the needs of the health-conscious homeowner in mind.
"Our current UV-400 air purifier sets a very high standard, and is unique in the marketplace, but was primarily conceived for the demands of the commercial marketplace," said Jack Lennon, President of UV Flu Technologies. "Our UV-400 kills airborne bacteria in larger spaces up to 700-900 sq. feet, whereas typical HEPA filter units generally cover a space from 100-200 sq. feet. Our unit keeps on killing contaminants long after the filter units have lost their efficacy as they are not dependent on changing, or washing filters continuously."
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Announces-iw-4156153299.html?x=0&.v=1
Website: http://www.uvflutech.com/
UV Flu Technologies, Inc., Key Highlights
• FDA Approved as a Class II Medical device
• Extensive testing by EPA and FDA certified laboratories
confirm the proprietary system has over 99% effectiveness of eliminating bacteria
• The Company’s strategic differentiators include excellent independent test
results proving the effectiveness and safety of its products, proprietary design,
and FDA market clearance approving the sale of its products as medical
devices.
• The Company has been issued U.S. Patent No. 6939397 with 43 claims covering
its innovative removable cartridge, housing, UV chamber, UV radiation
source and baffle technology.
• UV Flu’s products are environmentally friendly. The energy efficient system
does not use or produce ozone, uses less energy than a 100 watt light bulb
and can qualify for Green Building programs.
• Experts have warned that a new type of drug-resistant superbug is emerging.
NDM-1 is a gene carried by bacteria that makes the strain resistant to some of
the most powerful antibiotics. NDM-1 can easily now jump from one strain of
bacteria to another.
PharmAthene, Inc. (AMEX: PIP)
PharmAthene, Inc. (AMEX: PIP) Recent News: “PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that based on information provided by PharmAthene in its compliance plan, and discussions with Exchange staff, the NYSE Amex LLC has determined that the Company made a reasonable demonstration of its ability to regain compliance with the NYSE Amex listing requirements and granted PharmAthene an extension until January 26, 2012 to demonstrate its compliance. ”
Full Article: http://finance.yahoo.com/news/PharmAthene-Listing-prnews-3514960700.html?x=0&.v=1
About PharmAthene, Inc. (AMEX: PIP): PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
Third generation rPA anthrax vaccine
Valortim(R)-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
For more information about PharmAthene, please visit http://www.pharmathene.com/ .
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech/pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our global stock directories.
Disclaimer: The following news is paid for by a third party on behalf of UV Flu Technologies, Inc., (three thousand per month) as a showcase stock. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA –October 17, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research for investors, reports on recent Biotech/ Pharma Stocks news and trading. Biotech Stocks to follow for Monday morning include UV Flu Technologies, Inc., (OTCBB: UVFT), PharmAthene, Inc. (AMEX: PIP), VIVUS Inc (NASDAQ:VVUS), and Amgen Inc., (NASDAQ: AMGN).
Biotech Sector Snapshot: (Trading at Market close Friday October 15)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.27
PharmAthene, Inc. (AMEX: PIP), trading at $ 3.19, up 1.21 (61.11%) on Volume of 22,685 ,355 shares
VIVUS Inc (NASDAQ:VVUS), trading at $6.53, (0.76 %)
Amgen Inc., (NASDAQ: AMGN) trading at $ 56.71, up 1.85 (3.37%)
Biotech Stocks to Watch; Recent News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
Latest News:
UV Flu Technologies Announces Development of Residential Market Bacteria Killing Indoor Air Purifier to Be Based on Laboratory Proven Design
“UV Flu Technologies, Inc. is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace. The new unit will be designated UV-200 and will be designed with the needs of the health-conscious homeowner in mind.
"Our current UV-400 air purifier sets a very high standard, and is unique in the marketplace, but was primarily conceived for the demands of the commercial marketplace," said Jack Lennon, President of UV Flu Technologies. "Our UV-400 kills airborne bacteria in larger spaces up to 700-900 sq. feet, whereas typical HEPA filter units generally cover a space from 100-200 sq. feet. Our unit keeps on killing contaminants long after the filter units have lost their efficacy as they are not dependent on changing, or washing filters continuously."
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Announces-iw-4156153299.html?x=0&.v=1
Website: http://www.uvflutech.com/
UV Flu Technologies, Inc., Key Highlights
• FDA Approved as a Class II Medical device
• Extensive testing by EPA and FDA certified laboratories
confirm the proprietary system has over 99% effectiveness of eliminating bacteria
• The Company’s strategic differentiators include excellent independent test
results proving the effectiveness and safety of its products, proprietary design,
and FDA market clearance approving the sale of its products as medical
devices.
• The Company has been issued U.S. Patent No. 6939397 with 43 claims covering
its innovative removable cartridge, housing, UV chamber, UV radiation
source and baffle technology.
• UV Flu’s products are environmentally friendly. The energy efficient system
does not use or produce ozone, uses less energy than a 100 watt light bulb
and can qualify for Green Building programs.
• Experts have warned that a new type of drug-resistant superbug is emerging.
NDM-1 is a gene carried by bacteria that makes the strain resistant to some of
the most powerful antibiotics. NDM-1 can easily now jump from one strain of
bacteria to another.
PharmAthene, Inc. (AMEX: PIP)
PharmAthene, Inc. (AMEX: PIP) Recent News: “PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that based on information provided by PharmAthene in its compliance plan, and discussions with Exchange staff, the NYSE Amex LLC has determined that the Company made a reasonable demonstration of its ability to regain compliance with the NYSE Amex listing requirements and granted PharmAthene an extension until January 26, 2012 to demonstrate its compliance. ”
Full Article: http://finance.yahoo.com/news/PharmAthene-Listing-prnews-3514960700.html?x=0&.v=1
About PharmAthene, Inc. (AMEX: PIP): PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
Third generation rPA anthrax vaccine
Valortim(R)-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
For more information about PharmAthene, please visit http://www.pharmathene.com/ .
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech/pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our global stock directories.
Disclaimer: The following news is paid for by a third party on behalf of UV Flu Technologies, Inc., (three thousand per month) as a showcase stock. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Thursday, October 14, 2010
Investorideas.com - Pharma/Biotech Stocks Volume Movers; OTC Market Leaders on the Move ($1.00-$2.00): (OTCBB: TTNP, ALME, NNVC, ALIF)
Investorideas.com - Pharma/Biotech Stocks Volume Movers; OTC Market Leaders on the Move ($1.00-$2.00): (OTCBB: TTNP, ALME, NNVC, ALIF)
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) October 14, 2010 - OTC VOLUME LEADERS www.otcvolumeleaders.com, reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include Titan Pharmaceuticals Inc (OTCBB: TTNP), (OTCBB: NNVC), Alamo Energy Corp (OTCBB: ALME), and Artificial Life, Inc. (OTCBB: ALIF).
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link below
http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
Pharma Stocks:
One of the OTCBB volume leaders; Recent News: "Titan Pharmaceuticals, Inc. today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA). The article highlights data from the 163-patient trial, which showed that patients receiving Titan's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study."
Full Article: http://finance.yahoo.com/news/Titan-Pharmaceuticals-prnews-3848273001.html?x=0&.v=1
Market Snapshot: (at time of release)
Dow 11,069.52 -26.56 -0.24%
Nasdaq 2,433.97 -7.26 -0.30%
S&P 500 1,172.26 -5.84 -0.50%
10 Yr Bond(%) 2.4720% +0.4100
Oil 82.62 -0.39 -0.47%
Gold 1,373.80 +4.30 +0.31%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/
Source http://www.otcvolumeleaders.com/
Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com
Request News and Info on OTC
Investors - Get OTC stock quotes from http://www.otcmarkets.com
Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) October 14, 2010 - OTC VOLUME LEADERS www.otcvolumeleaders.com, reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($1.00-$2.00) include Titan Pharmaceuticals Inc (OTCBB: TTNP), (OTCBB: NNVC), Alamo Energy Corp (OTCBB: ALME), and Artificial Life, Inc. (OTCBB: ALIF).
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link below
http://bit.ly/otcvolumeleaders
OTC/Market Commentary:
Pharma Stocks:
One of the OTCBB volume leaders; Recent News: "Titan Pharmaceuticals, Inc. today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA). The article highlights data from the 163-patient trial, which showed that patients receiving Titan's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study."
Full Article: http://finance.yahoo.com/news/Titan-Pharmaceuticals-prnews-3848273001.html?x=0&.v=1
Market Snapshot: (at time of release)
Dow 11,069.52 -26.56 -0.24%
Nasdaq 2,433.97 -7.26 -0.30%
S&P 500 1,172.26 -5.84 -0.50%
10 Yr Bond(%) 2.4720% +0.4100
Oil 82.62 -0.39 -0.47%
Gold 1,373.80 +4.30 +0.31%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/
Source http://www.otcvolumeleaders.com/
Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com
Request News and Info on OTC
Investors - Get OTC stock quotes from http://www.otcmarkets.com
Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference
LINCOLNSHIRE, Ill. - October 14, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.
Stephen M. Simes, BioSante's president & chief executive officer, will speak at 11:00 am EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials, as well as comment on the receipt of FDA orphan drug designation received for several of the cancer vaccines.
The agenda for the Cancer Immunotherapy: A Long Awaited Reality conference includes keynotes and plenary discussions, roundtable lunch conversations with experts, a focused science and industry track, as well as networking opportunities. The conference will be hosted by MD Becker Partners and BioBusiness.TV. There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine. Jill O'Donnell-Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), is scheduled to present a keynote address titled "The Future of Cancer Vaccine Development."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. In early April 2010, MD Becker Partners published a 150-page industry report titled "Cancer Vaccine Therapies: Failures and Future Opportunities," which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discussion of the scientific, clinical, and commercial considerations for major industry participants. For more information visit http://www.mdbpartners.com.
About BioBusiness.TV
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. For more information, visit http://www.biobusiness.tv.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
LINCOLNSHIRE, Ill. - October 14, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.
Stephen M. Simes, BioSante's president & chief executive officer, will speak at 11:00 am EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials, as well as comment on the receipt of FDA orphan drug designation received for several of the cancer vaccines.
The agenda for the Cancer Immunotherapy: A Long Awaited Reality conference includes keynotes and plenary discussions, roundtable lunch conversations with experts, a focused science and industry track, as well as networking opportunities. The conference will be hosted by MD Becker Partners and BioBusiness.TV. There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine. Jill O'Donnell-Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), is scheduled to present a keynote address titled "The Future of Cancer Vaccine Development."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. In early April 2010, MD Becker Partners published a 150-page industry report titled "Cancer Vaccine Therapies: Failures and Future Opportunities," which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discussion of the scientific, clinical, and commercial considerations for major industry participants. For more information visit http://www.mdbpartners.com.
About BioBusiness.TV
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. For more information, visit http://www.biobusiness.tv.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Tuesday, October 12, 2010
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Presents LibiGel® Clinical Study Update at North American Menopause Society Meeting
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Presents LibiGel® Clinical Study Update at North American Menopause Society Meeting
Adjudicated Cardiovascular Events Continue to Be Lower Than Expected
LINCOLNSHIRE, Ill. - October 12, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) presented a LibiGel clinical study update at the 21st Annual Meeting of The North American Menopause Society (NAMS) on October 8, 2010, with more than 1,000 experts and practitioners in menopause and women's health in attendance.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, presented an update entitled, "LibiGel® (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events." LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
Dr. Snabes presented data, based on approximately 2,300 women in the safety study for an average of approximately 10.5 months each, showing there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, and only seven diagnoses of breast cancer, a rate of approximately 0.32 percent. "If testosterone increased CV disease, we would expect to see a higher CV event rate, especially since the study subjects are at the higher end of cardiovascular risk for the intended treatment population. Based on the safety seen to date, we believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD," stated Dr. Snabes.
In addition, BioSante sponsored a symposium entitled, "Sexual Quality of Life with Aging." The moderator of the symposium was Steven R. Goldstein, MD, FACOD, CCD, NCMP, Professor of Obstetrics and Gynecology, New York University School of Medicine and the next president of NAMS. Jan L. Shifren, MD, NCMP, Associate Professor of Obstetrics, Gynecology, & Reproductive Biology at Harvard Medical School, and Director of the Menopause Program at Massachusetts General Hospital spoke on the "Prevalence of Sexual Function & Distress Across the Lifespan for Women." Sheryl A. Kingsberg, PhD, Division Chief, Obstetrics & Gynecology, Behavior Medicine at the University Hospitals Case Medical Center, and Professor, Case Western Reserve University in Cleveland, Ohio covered the topic entitled, "Treatment Options for Postmenopausal Women With Sexual Dysfunction."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Adjudicated Cardiovascular Events Continue to Be Lower Than Expected
LINCOLNSHIRE, Ill. - October 12, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) presented a LibiGel clinical study update at the 21st Annual Meeting of The North American Menopause Society (NAMS) on October 8, 2010, with more than 1,000 experts and practitioners in menopause and women's health in attendance.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, presented an update entitled, "LibiGel® (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events." LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
Dr. Snabes presented data, based on approximately 2,300 women in the safety study for an average of approximately 10.5 months each, showing there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, and only seven diagnoses of breast cancer, a rate of approximately 0.32 percent. "If testosterone increased CV disease, we would expect to see a higher CV event rate, especially since the study subjects are at the higher end of cardiovascular risk for the intended treatment population. Based on the safety seen to date, we believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD," stated Dr. Snabes.
In addition, BioSante sponsored a symposium entitled, "Sexual Quality of Life with Aging." The moderator of the symposium was Steven R. Goldstein, MD, FACOD, CCD, NCMP, Professor of Obstetrics and Gynecology, New York University School of Medicine and the next president of NAMS. Jan L. Shifren, MD, NCMP, Associate Professor of Obstetrics, Gynecology, & Reproductive Biology at Harvard Medical School, and Director of the Menopause Program at Massachusetts General Hospital spoke on the "Prevalence of Sexual Function & Distress Across the Lifespan for Women." Sheryl A. Kingsberg, PhD, Division Chief, Obstetrics & Gynecology, Behavior Medicine at the University Hospitals Case Medical Center, and Professor, Case Western Reserve University in Cleveland, Ohio covered the topic entitled, "Treatment Options for Postmenopausal Women With Sexual Dysfunction."
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Tuesday, October 5, 2010
Biotech News; UV Flu Technologies (OTC.BB:UVFT) Announces Development of Residential Market Bacteria Killing Indoor Air Purifier to Be Based on Laboratory Proven Design
Biotech News; UV Flu Technologies (OTC.BB:UVFT) Announces Development of Residential Market Bacteria Killing Indoor Air Purifier to Be Based on Laboratory Proven Design
Smaller Home Unit to Deliver Health Benefits Based on Success of Commercial Grade UV-400
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA – October 5, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace. The new unit will be designated UV-200 and will be designed with the needs of the health-conscious homeowner in mind.
(OTCBB: AQUM)"Our current UV-400 air purifier sets a very high standard, and is unique in the marketplace, but was primarily conceived for the demands of the commercial marketplace," said Jack Lennon, President of UV Flu Technologies. "Our UV-400 kills airborne bacteria in larger spaces up to 700-900 sq. feet, whereas typical HEPA filter units generally cover a space from 100-200 sq. feet. Our unit keeps on killing contaminants long after the filter units have lost their efficacy as they are not dependent on changing, or washing filters continuously."
Mr. Lennon further notes, "Doctors have provided feedback to us that indicated they were reluctant to recommend air filters to their patients, because if the patients did not faithfully change or wash the filters at prescribed intervals, they could end up getting sicker from the infected air leaving the unit through the dirty filter. Our technology uses Hi Intensity Germicidal UV light, which kills organic contaminants that pass through the unit and isn't dependent on a filter medium that captures, but doesn't kill, bacteria and other contaminants."
"Our residential unit will use the same technology, but will be designed for smaller spaces, and will incorporate new features to make it easier to transport from room-to-room, such as between children's bedrooms. The UV-200 as planned, will offer features designed specifically for allergy relief, as well. We look forward to making these units available as soon as possible and invite interested individuals to contact us today to find out more," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Source: UV Flu Technologies, Inc.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Smaller Home Unit to Deliver Health Benefits Based on Success of Commercial Grade UV-400
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA – October 5, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace. The new unit will be designated UV-200 and will be designed with the needs of the health-conscious homeowner in mind.
(OTCBB: AQUM)"Our current UV-400 air purifier sets a very high standard, and is unique in the marketplace, but was primarily conceived for the demands of the commercial marketplace," said Jack Lennon, President of UV Flu Technologies. "Our UV-400 kills airborne bacteria in larger spaces up to 700-900 sq. feet, whereas typical HEPA filter units generally cover a space from 100-200 sq. feet. Our unit keeps on killing contaminants long after the filter units have lost their efficacy as they are not dependent on changing, or washing filters continuously."
Mr. Lennon further notes, "Doctors have provided feedback to us that indicated they were reluctant to recommend air filters to their patients, because if the patients did not faithfully change or wash the filters at prescribed intervals, they could end up getting sicker from the infected air leaving the unit through the dirty filter. Our technology uses Hi Intensity Germicidal UV light, which kills organic contaminants that pass through the unit and isn't dependent on a filter medium that captures, but doesn't kill, bacteria and other contaminants."
"Our residential unit will use the same technology, but will be designed for smaller spaces, and will incorporate new features to make it easier to transport from room-to-room, such as between children's bedrooms. The UV-200 as planned, will offer features designed specifically for allergy relief, as well. We look forward to making these units available as soon as possible and invite interested individuals to contact us today to find out more," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Source: UV Flu Technologies, Inc.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Subscribe to:
Posts (Atom)